[6-K] National Energy Services Reunited Corp. Warrant Current Report (Foreign Issuer)

Rhea-AI Filing Summary

On 30 June 2025, GSK plc (GSK) repurchased 483,834 ordinary shares (nominal value 31¼ p) through its broker Merrill Lynch International under the non-discretionary buyback agreement announced on 4 June 2025.

• Price range: 1,385.50p – 1,405.00p
• Volume-weighted average price: 1,397.42p
• Cash outlay: ≈ £6.8 million

Since the start of the programme (4 June 2025) the company has reacquired 8,038,188 shares. Following the latest trade GSK holds 226,172,571 shares in treasury, leaving 4,089,197,628 shares outstanding (treasury stock equals 5.53 % of voting rights).

The transaction reduces the free float by roughly 0.012 %; while financially immaterial, it signals continuing capital-return discipline and fulfils UK Disclosure Guidance & Transparency Rule obligations. Detailed venue- and trade-level data accompany the filing for regulatory transparency.

Positive

• Continuation of authorised buyback programme demonstrates ongoing shareholder-return focus.
• 8.0 million shares repurchased since 4 June 2025, indicating steady execution.
• Treasury shares now 5.53 % of voting rights, providing flexibility for future capital management.

Negative

• Latest tranche represents only 0.012 % of shares outstanding, offering a negligible immediate boost to EPS or valuation.
• No disclosure of total programme size or remaining authorisation, limiting insight into future buyback magnitude.

Insights

Equity Research Analyst

TL;DR – Routine buyback of 0.012 % of shares; negligible EPS lift, neutral valuation impact.

GSK’s latest 6-K shows another tranche of its June 2025 buyback: 483.8k shares at a 1,397p VWAP. The £6.8 m spend is minimal versus a £70 bn market cap and outstanding share count of 4.1 bn, trimming float by only 0.012 %. Cumulatively 8.0 m shares have been acquired this month, still <0.2 % of share capital. While supportive to per-share metrics and a signal of balance-sheet capacity, the transaction has no material effect on valuation or leverage. Rating: neutral impact.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-38091

NATIONAL ENERGY SERVICES REUNITED CORP.

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of registrant’s name into English)

777 Post Oak Blvd., Suite 730

Houston, Texas 77056

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

The information and related exhibits contained in this Report on Form 6-K are hereby incorporated by reference into National Energy Services Reunited Corp.’s Registration Statement on Form S-8 (File No. 333-280902).

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Expiration of Exchange Offer and Consent Solicitation

On July 1, 2025, National Energy Services Reunited Corp., a British Virgin Islands company (the “Company”), issued a press release announcing the results of the Company’s previously announced offer (the “Offer”) to each holder of the Company’s outstanding warrants (the “Warrants”) to purchase ordinary shares of the Company, no par value (the “Ordinary Shares”), to receive 0.10 Ordinary Shares in exchange for each outstanding Warrant tendered by the holder and exchanged pursuant to the Offer. Concurrently with the Offer, the Company solicited consents from holders of the Warrants to amend the warrant agreement governing the Warrants (the “Consent Solicitation”). The Warrants trade on the Nasdaq Capital Market under the symbol “NESRW.”

The Company also announced that the Registration Statement on Form F-4, originally filed by the Company with the Securities and Exchange Commission on May 30, 2025, as amended on June 23, 2025, was declared effective on June 24, 2025.

A copy of the press release announcing the expiration and results of the Offer and Consent Solicitation is attached as Exhibit 99.1 and is incorporated by reference herein.

The following exhibit is being filed herewith:

Exhibit No.		Description
99.1		Press Release, dated July 1, 2025.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NATIONAL ENERGY SERVICES REUNITED CORP.
Date: July 1, 2025	By:	/s/ Stefan Angeli
	Name:	Stefan Angeli
	Title:	Chief Financial Officer

3

FAQ

How many GSK (GSK) shares were repurchased on 30 June 2025?

483,834 ordinary shares were bought back on 30 June 2025.

What price did GSK pay for the repurchased shares?

The company paid between 1,385.50p and 1,405.00p per share; VWAP was 1,397.42p.

How many shares has GSK bought since launching the June 2025 buyback?

Since 4 June 2025, GSK has repurchased 8,038,188 shares.

What is GSK’s share count after the transaction?

GSK has 4,089,197,628 ordinary shares in issue (excluding treasury) and 226,172,571 shares held in treasury.

What percentage of voting rights do GSK’s treasury shares represent?

Treasury shares represent 5.53 % of the company’s voting rights.

Why does GSK disclose detailed trade information in the 6-K?

To comply with the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (DTR 5.5.1R).